A clinical study testing an oral therapy to reduce cardiovascular inflammation risk. Read for trial design details and industry context.
Key Takeaways
- QUELL-CV will randomize approximately 160 adults in a 12-week dose-ranging Phase 2 trial
- Primary endpoint is percent change in high-sensitivity C-reactive protein
- Phase 1 study showed median hsCRP reductions of 86% at selected doses